

# Nicholas James

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5896203/publications.pdf>

Version: 2024-02-01

86  
papers

13,092  
citations

101543

36  
h-index

60623

81  
g-index

87  
all docs

87  
docs citations

87  
times ranked

10778  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. <i>European Urology Oncology</i> , 2023, 6, 67-75.   | 5.4  | 12        |
| 2  | Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.  | 1.6  | 40        |
| 3  | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.  | 13.7 | 173       |
| 4  | Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 461-461.  | 1.6  | 0         |
| 5  | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.   | 12.8 | 3         |
| 6  | Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.   | 5.1  | 29        |
| 7  | Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2022, 23, 650-658.   | 10.7 | 16        |
| 8  | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.  | 1.9  | 51        |
| 9  | Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2092.   | 7.4  | 108       |
| 10 | Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway. <i>BJU International</i> , 2022, 129, 691-694.  | 2.5  | 0         |
| 11 | Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. <i>Genome Medicine</i> , 2022, 14, .   | 8.2  | 5         |
| 12 | Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.   | 2.5  | 4         |
| 13 | Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.   | 8.4  | 35        |
| 14 | Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021, 79, 307-315.  | 1.9  | 20        |
| 15 | Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology, The</i> , 2021, 22, 246-255.  | 10.7 | 73        |
| 16 | Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 440-440.  | 1.6  | 1         |
| 17 | Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 555.  | 7.1  | 66        |
| 18 | Reply to Santhanam Sundar and Paul Symonds™ Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-15. <i>European Urology</i> , 2021, 80, e51-e52. | 1.9  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. <i>BJU International</i> , 2021, , .   | 2.5  | 3         |
| 20 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.  | 10.7 | 61        |
| 21 | Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.  | 1.9  | 58        |
| 22 | Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1413-1421.   | 13.7 | 226       |
| 23 | Survey of the Impact of COVID-19 on Oncologists'™ Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1248-1257.  | 1.8  | 33        |
| 24 | Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. <i>Frontiers in Oncology</i> , 2020, 10, 812.   | 2.8  | 11        |
| 25 | The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's â€œM1   RT Comparisonâ€. <i>European Urology Oncology</i> , 2020, 3, 412-419.   | 5.4  | 9         |
| 26 | Reply to Wei Liu, Xiaoping Liu, Sheng Li's™ Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>Eur Urol</i> 2020;77:260â€“8. <i>European Urology</i> , 2020, 77, e156-e157. | 1.9  | 0         |
| 27 | CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. <i>Scientific Reports</i> , 2020, 10, 342.   | 3.3  | 13        |
| 28 | Abiraterone in â€œHigh-â€and â€œLow-riskâ€Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.   | 1.9  | 142       |
| 29 | Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.  | 1.9  | 48        |
| 30 | This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.   | 1.6  | 42        |
| 31 | Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019, 20, 294.   | 1.6  | 37        |
| 32 | Targeted deep sequencing of urothelial bladder cancers and associated urinary <scp>DNA</scp>: a 23â€gene panel with utility for nonâ€invasive diagnosis and risk stratification. <i>BJU International</i> , 2019, 124, 532-544.  | 2.5  | 47        |
| 33 | Healthâ€related quality of life around the time of diagnosis in patients with bladder cancer. <i>BJU International</i> , 2019, 124, 984-991.  | 2.5  | 16        |
| 34 | Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.   | 1.9  | 117       |
| 35 | Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently. <i>European Urology Focus</i> , 2019, 5, 119-122.  | 3.1  | 8         |
| 36 | Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2019, 5, 263-272.  | 0.4  | 10        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 294-301.  | 5.4  | 38        |
| 38 | Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5030-5030. | 1.6  | 4         |
| 39 | Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. <i>BJU International</i> , 2018, 121, 680-683.  | 2.5  | 15        |
| 40 | Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.   | 5.4  | 19        |
| 41 | Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.   | 13.7 | 901       |
| 42 | Prognostic and predictive models in hormone-sensitive prostate cancer. <i>BJU International</i> , 2018, 122, 352-353.  | 2.5  | 1         |
| 43 | Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228â€Š&gt;A/T Mutation. <i>Bladder Cancer</i> , 2018, 4, 41-48.  | 0.4  | 40        |
| 44 | Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. <i>Scientific Reports</i> , 2018, 8, 11290.   | 3.3  | 28        |
| 45 | Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 162-162.   | 1.6  | 5         |
| 46 | Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. <i>Oncotarget</i> , 2018, 9, 25244-25253.  | 1.8  | 12        |
| 47 | UroMarkâ€Ša urinary biomarker assay for the detection of bladder cancer. <i>Clinical Epigenetics</i> , 2017, 9, 8.   | 4.1  | 81        |
| 48 | Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.  | 27.0 | 1,315     |
| 49 | Testing many treatments within a single protocol over 10â€Šyears at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.   | 1.6  | 59        |
| 50 | Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.  | 2.8  | 128       |
| 51 | Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. <i>Eur Urol</i> 2016;70:707â€Š708. <i>European Urology</i> , 2017, 72, e17.                   | 1.9  | 0         |
| 52 | Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.   | 3.8  | 3         |
| 53 | Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.   | 1.6  | 54        |
| 54 | Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA5003-LBA5003.   | 1.6  | 2         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. Journal of Clinical Oncology, 2017, 35, LBA5003-LBA5003.   | 1.6  | 6         |
| 56 | BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2017, 35, 280-280.                                | 1.6  | 15        |
| 57 | Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level.. Journal of Clinical Oncology, 2017, 35, 292-292. | 1.6  | 1         |
| 58 | Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT).. Journal of Clinical Oncology, 2017, 35, 298-298.  | 1.6  | 27        |
| 59 | Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team. JMIR Research Protocols, 2017, 6, e147.  | 1.0  | 7         |
| 60 | Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. European Urology, 2016, 70, 906-908.  | 1.9  | 51        |
| 61 | STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply. Lancet, The, 2016, 388, 235-236.   | 13.7 | 6         |
| 62 | Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. European Journal of Human Genetics, 2016, 24, 1167-1174.  | 2.8  | 115       |
| 63 | A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research. Medical Decision Making, 2016, 36, 321-334.   | 2.4  | 9         |
| 64 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177.                           | 13.7 | 1,570     |
| 65 | Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology, The, 2016, 17, 243-256.   | 10.7 | 361       |
| 66 | Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. JAMA Oncology, 2016, 2, 348.  | 7.1  | 155       |
| 67 | Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).. Journal of Clinical Oncology, 2016, 34, 162-162.   | 1.6  | 6         |
| 68 | Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.   | 2.5  | 66        |
| 69 | Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 338.e1-338.e7.  | 1.6  | 32        |
| 70 | A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. European Urology Focus, 2015, 1, 82-89.  | 3.1  | 10        |
| 71 | Defining Bowel Dose Volume Constraints for Bladder Radiotherapy Treatment Planning. Clinical Oncology, 2015, 27, 22-29.  | 1.4  | 18        |
| 72 | Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Research, 2015, 35, 1057-63.  | 1.1  | 9         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. <i>Drug Design, Development and Therapy</i> , 2014, 9, 13.           | 4.3  | 8         |
| 74 | Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.  | 1.9  | 56        |
| 75 | Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746. | 10.7 | 433       |
| 76 | A comparison of patient and tumour characteristics in two <scp>UK</scp> bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013, 112, 169-175.   | 2.5  | 35        |
| 77 | Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.  | 1.6  | 121       |
| 78 | Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011, 12, .   | 1.6  | 10        |
| 79 | The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010, 105, 784-788.   | 2.5  | 52        |
| 80 | Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009, 10, 39.   | 1.6  | 120       |
| 81 | Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009, 103, 464-469.   | 2.5  | 86        |
| 82 | Biology of testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1659-1673.   | 2.4  | 19        |
| 83 | Speeding up the Evaluation of New Agents in Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1204-1214.  | 6.3  | 126       |
| 84 | Endocrine therapy and other targeted therapies for metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1179-1195.  | 2.4  | 9         |
| 85 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1502-1512.   | 27.0 | 5,142     |
| 86 | Homocysteine-Induced Inhibition of Endothelium-Dependent Relaxation in Rabbit Aorta. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 422-427.  | 2.4  | 189       |